Collaboration Will Help Match the Right Patient With the Right Trial
The collaboration between med fusion and GenomOncology promises improved outcomes in personalized cancer trials.
med fusion, an integrated molecular center of excellence and clinical trials service organization and GenomOncology, an Ohio based genomics technology and services provider, today announced a partnership to optimize treatment strategies based on the patient’s disease state and tumor profile. The companies believe that GenomOnoclogy’s proprietary technology platform, the GO Clinical WorkbenchTM, and support services will complement med fusion’s expanded solid tumor disease-specific panels and deliver a comprehensive laboratory report detailing relevant drug and clinical trial options.
Press release:
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025